Vidarbha News

Multiple Myeloma Market in 7MM is expected to witness a major change in the study period 2019-2032

 Breaking News
  • No posts were found

Multiple Myeloma Market in 7MM is expected to witness a major change in the study period 2019-2032

November 22
17:20 2022
Multiple Myeloma Market in 7MM is expected to witness a major change in the study period 2019-2032

The Multiple Myeloma Market is anticipated to show positive growth, mainly attributed to the increasing incident cases and also, the launch of upcoming therapies during the forecast period. Moreover, the advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medical development.

 

The Multiple Myeloma market research report provides current treatment practices, Multiple Myeloma emerging drugs, and Multiple Myeloma market share of the individual therapies, current and forecasted 7MM Multiple Myeloma market size. The Multiple Myeloma market report also covers current Multiple Myeloma treatment practice, SWOT analysis, and Multiple Myeloma unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Key takeaways from the Multiple Myeloma Market Research Report

  • In the year 2020, the total Multiple Myeloma incident case was 91,693 cases in the 8MM. The United States, in 2020, accounted for 32,270 cases (the highest number), which will probably rise by the year 2030. Among the EU-5 countries, the highest number of incident cases of Multiple Myeloma in the year 2020, was in Germany. In China, the total number of incident cases of Multiple Myeloma was 21,116 in 2020, and this number is expected to rise throughout the forecast period.
  • The leading Multiple Myeloma Companies are working such as GlaxoSmithKline, Bristol-Myers Squibb/Bluebird bio, Oncopeptides AB, Secura Bio, Amgen (Onyx therapeutics), Takeda Pharmaceutical (Millennium Pharmaceuticals), Sanofi, Karyopharm Therapeutics, Janssen Biotech, Bristol Myers Squibb/AbbVie, Takeda Pharmaceutical/Janssen Pharmaceutical, Bristol-Myers Squibb Company (Celgene), Celgene (BMS), Bristol-Myers Squibb/Celgene, RAPA Therapeutics, Pfizer (Array Biopharma),  Cellectar Biosciences, BioLineRx, Celgene/Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie/Genentech (Roche), Janssen Biotech/Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Janssen, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Cartesian Therapeutics, AstraZeneca, Abbvie (Pharmacyclics) and Johnson & Johnson, MorphoSys AG/I-Mab Biopharmam, and others.
  • Promising Multiple Myeloma Pipeline therapies such as belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Elotuzumab, Bortezomib, BT062, bb2121, Venetoclax, Bortezomib, Melphalan, Panobinostat, VELCADE (bortezomib), cyclophosphamide, and others.

 

Recent Developmental Activities in the Multiple Myeloma Pipeline

  • In June 2021, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the USFDA has granted Breakthrough Therapy Designation for teclistamab in the treatment of relapsed or refractory multiple myeloma. This distinction for teclistamab, an off-the-shelf, T-cell redirecting, a bispecific antibody targeting both BCMA and CD3 receptors, follows a PRIME designation from the EMA received earlier this year.
  • In May 2021, Oncopeptides has announced positive results from the OCEAN study, which compared the effectiveness and safety of melflufen with pomalidomide in patients with relapsed refractory multiple myeloma. The phase III OCEAN study is a global, randomized, head-to-head, open-label study, evaluating the efficacy and safety of melflufen and dexamethasone, versus pomalidomide and dexamethasone in patients with relapsed refractory multiple myeloma who have received 2-4 prior therapies.
  • In May 2021, the USFDA granted priority review to the Biologics License Applications (BLA) for ciltacabtagene autoleucel for the treatment of patients with relapsed/refractory multiple myeloma. The regulatory agency is expected to decide on the application by November 29, 2021, under the Prescription Drug User Fee Act.
  • In April 2021, Legend Biotech announced the submission of a MAA to the EMA seeking approval of ciltacabtagene autoleucel for the treatment of patients with relapsed and/or refractory multiple myeloma. The EMA’s Committee for Medicinal Products for Human Use (CHMP) granted accelerated assessment for this MAA.
  • In March 2019, the Janssen Pharmaceutical Companies of Johnson & Johnson has announced that the National Institute for Health and Care Excellence (NICE) has recommended Darzalex (daratumumab) plus Velcade (bortezomib) and dexamethasone (DVd) for use within the Cancer Drugs Fund (CDF), as an option for treating relapsed multiple myeloma in people who have had one previous treatment. Patients at the second line will now have access to a treatment combination, which NICE accepts had a ‘clinically important and statistically significant effect on progression-free survival.
  • With effect from August 2020, the Medicaid and NC Health Choice programs cover belantamab mafodotin-blmf for injection, for intravenous use (Blenrep) for use in the Physician Administered Drug Program (PADP) when billed with HCPCS code. Belantamab mafodotin-blmf is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent (NCDHHS, 2020).

 

Discover more about therapies set to grab major Multiple Myeloma market research report @ Multiple Myeloma Market Size

 

Multiple Myeloma Overview

Multiple myeloma is a cancer of plasma cells. In general, when plasma cells become cancerous and grow out of control, this is called multiple myeloma. The plasma cells make an abnormal protein (antibody) known by several different names, including monoclonal immunoglobulin, monoclonal protein (M-protein), M-spike, or paraprotein. Normal plasma cells are found in the bone marrow and are a significant part of the immune system. Multiple myeloma is the second most common blood cancer diagnosis, after non-Hodgkin lymphoma, in the United States.

Multiple myeloma is slightly more prevalent in males compared to females. Myeloma incidence is strongly related to age, with the highest incidence rates being in older people and most frequently diagnosed among people aged 65–74. Approximately 95% of cases are diagnosed at a distant stage or metastatic stage and 5-year relative survival rate for this stage is around 53%. Most of the researchers are unaware of the exact cause of multiple myeloma. However, they have made progress in understanding how certain changes in DNA can make plasma cells become cancerous. DNA is the chemical that transfers the instructions for nearly everything the cells do in the body. Patients with active myeloma generally receive treatment aimed at reducing or at least providing relief from symptoms and reducing the number of myeloma cells in the bone marrow.

 

Multiple myeloma Epidemiology Segmentation in the 7MM

  • Total Multiple myeloma Incidence
  • Total Multiple myeloma Symptomatic Cases
  • Total Multiple myeloma Incident Cases Segmented by Gender
  • Total Multiple myeloma Diagnosed cases by Age Distribution
  • Total Multiple myeloma Cases by Line of Treatment] scenario

 

Download the report to understand which factors are driving Multiple myeloma market trends @ Multiple myeloma Market Share

 

Multiple Myeloma Treatment Market

The main Multiple myelomatreatment options include stem cell transplant, chemotherapy, targeted therapy, corticosteroids, proteasome inhibitors, immunomodulators, monoclonal antibodies, surgery, and radiation therapy. Also, the survival of patients with myeloma has improved due to the development and approval of new treatments. MM treatment strategies have also evolved with the emergence of new therapies with a novel mechanism of action and also with more complex combination regimens being used, such as quadruplets, triplets, and doublets.

 

Multiple Myeloma Marketed Drugs 

Blenrep (Belantamab Mafodotin /GSK2857916): GlaxoSmithKline

GlaxoSmithKline’s lead candidate, Belantamab Mafodotin (GSK2857916) is a first-in-class, anti-BCMA immunoconjugate with an afucosylated, humanized IgG1 anti-BCMA monoclonal antibody conjugated by a protease-resistant maleimidocaproyl linker to a microtubule-disrupting agent, monomethyl auristatin F (MMAF). The drug linker technology is licensed from Seattle Genetics; monoclonal antibody is produced using POTELLIGENT Technology licensed from BioWa. It was approved by UDFDA and the European Commission in August 2020. This drug has received orphan drug designation from the EMA and the US FDA for multiple myeloma. Apart from this, the EMA and the US FDA have also granted PRIME designation and Breakthrough Therapy designation, respectively. 

Abecma (Idecabtagene vicleucel/bb2121/ ide-cel): Bristol-Myers Squibb/Bluebird bio

Abecma (ide-cel) is a B-cell maturation antigen (BCMA)-directed genetically modified autologous chimeric antigen receptor (CAR) T cell immunotherapy co-developed, and co-promoted by Bristol Myers Squibb and Bluebird bio for the treatment of adult patients with multiple myeloma who have received at least three prior therapies. In March 2021, the USFDA approved Abecma for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. This is the first FDA-approved cell-based gene therapy for multiple myeloma. 

Pepaxto (melflufen/ melphalan flufenamide): Oncopeptides AB

Pepaxto is a first-in-class anti-cancer peptide-drug conjugate that rapidly produces an alkylating payload into tumor cells. It is promptly taken up by myeloma cells due to its high lipophilicity and is immediately cleaved by peptidases to deliver an entrapped hydrophilic alkylator payload. Peptidases play a key role in protein homeostasis and feature in cellular processes such as cell-cycle progression and programmed cell death. In February 2021, the USFDA approved Pepaxto in combination with dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma, who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. 

Sarclisa (Isatuximab): Sanofi

Sarclisa— a product of Sanofi is a monoclonal antibody that binds to the CD38 receptor on multiple myeloma cells. It is manufactured and designed to initiate programmed tumor cell death (apoptosis) and immunomodulatory activity. In December 2017, Isatuximab received Orphan Designation for the treatment of patients with Relapsed or Refractory Multiple Myeloma by the US FDA and EMA. 

Xpovio (Selinexor): Karyopharm

Karyopharm’ potential candidate Selinexor is an oral, first-in-class, selective inhibitor of nuclear export also known as SINE, compound. It has been approved by the US FDA in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. In April 2021, EMA validated the Company’s Type II Variation MAA, which seeks to expand the currently authorized indication for Nexpovio in the European Union to include, in combination with Velcade (bortezomib) and low-dose dexamethasone, the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Validation of the application confirms the submission is complete to begin the EMA’s review process. 

Darzalex (Daratumumab): Janssen Biotech

Darzalex (daratumumab) is a prescription medicine used to treat a type of blood cancer called multiple myeloma. Darzalex is not chemotherapy. It is a human IgG1k monoclonal antibody that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells. In November 2015, Darzalex first received the US FDA approval as a monotherapy for patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double refractory to a PI and an immunomodulatory agent. Recently, in April 2020, the US FDA approved Darzalex Faspro (daratumumab and hyaluronidase-fihj), a new subcutaneous formulation of daratumumab. Darzalex Faspro is approved in four regimens across five indications in multiple myeloma patients, including newly diagnosed, transplant-ineligible patients as well as relapsed or refractory patients.

 

Multiple Myeloma Emerging Drugs 

Venetoclax (ABT-199): AbbVie and Roche

Venetoclax (Venclexta, Venclyxto) is an oral B-cell lymphoma-2 (BCL-2) inhibitor developed by AbbVie and Genentech. It is used for the treatment of adult patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL) and in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude the use of intensive induction chemotherapy. In nonclinical studies, venetoclax has demonstrated cytotoxic activity in tumor cells that overexpress BCL-2. In March 2019, the US FDA placed a partial clinical hold on Venetoclax’s multiple myeloma trials after new safety concerns were raised during a review of the BELLINI Phase III trial (NCT02755597). In June 2019, the US FDA removed the partial clinical hold based upon agreement on revisions to the CANOVA study protocol (Myeloma Positive for the t(11;14) Genetic Abnormality), including new risk mitigation measures, protocol-specified guidelines, and updated futility criteria (AbbVie News Center, 2019). 

Ciltacabtagene Autoleucel (cilta-cel/ JNJ-4528/ JNJ-68284528/ LCAR-B38M): Janssen Biotech/Nanjing Legend Biotech

Ciltacabtagene Autoleucel is currently being investigated for the treatment of patients with multiple myeloma who have received at least three prior regimens, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody, and have documented disease progression within 12 months of starting the most recent therapy, or are double refractory to an immunomodulatory drug and a proteasome inhibitor. This product is being evaluated under licensing and collaboration agreements between Janssen and Legend Biotech. In the first quarter of 2021, the rolling submission of a Biologics License Application (BLA) to the USFDA was completed by Janssen, for cilta-cel, for the treatment of adults with relapsed or refractory multiple myeloma. Additionally, in April 2021, the company has also submitted the MAA to the EMA for cilta-cel (Legend Biotech, 2021b). 

REGN5458: Regeneron Pharmaceuticals

REGN5458 is a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma. BCMA (B-cell maturation antigen) is a protein that is typically over-expressed on multiple myeloma cells. In December 2019, the company presented the results at the American Society of Hematology (ASH) Annual Meeting. Currently, REGN5458 monotherapy is being investigated in an open-label, Phase I/II (NCT03761108) dose-escalation trial in patients with relapsed or refractory multiple myeloma who are at least triple refractory to existing therapeutic options, including proteasome inhibitors, immunomodulatory drugs, and CD38 antibody treatments. 

Iberdomide (CC-220): Bristol-Myers Squibb/Celgene

Iberdomide is an investigational cereblon E3 ligase modulator compound with enhanced tumoricidal and Immunostimulatory activities that induces degradation of transcription factors Aiolos and Ikaros, thereby inhibiting the growth of myeloma cells in vitro. In pre-clinical models, iberdomide has demonstrated the ability to destroy tumor cells, stimulate an immune response, overcome resistance to immunomodulatory drugs, and synergize with dexamethasone, daratumumab, and bortezomib (Celgene Corporation, 2019). In December 2018, the US FDA has granted orphan drug designation to iberdomide for the treatment of multiple myeloma.

 

Multiple Myeloma Key Companies and Pipeline Therapies

  • Venetoclax (ABT-199): AbbVie and Roche
  • JNJ-68284528 (LCAR-B38M/JNJ-4528): Janssen Biotech/Nanjing Legend Biotech
  • Keytruda (Pembrolizumab): Merck Sharp & Dohme Corp.
  • Cetrelimab (JNJ-63723283): Janssen Research & Development
  • REGN5458: Regeneron Pharmaceuticals
  • Felzartamab (MOR202): MorphoSys AG/I-Mab Biopharma
  • Chidamide (Epidaza): Chipscreen Biosciences
  • Iberdomide (CC-220): Bristol-Myers Squibb/Celgene
  • Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy: RAPA Therapeutics
  • Encorafenib in combination with Binimetinib: Pfizer (Array Biopharma)
  • CLR 131 (131-CLR1404): Cellectar Biosciences
  • BL-8040: BioLineRx
  • GVAX (GM-CSF) Vaccine: Celgene/Aduro Biotech
  • ECT-001: ExCellThera
  • TAK-079: Takeda
  • GBR 1342 (ISB 1342): Glenmark (Ichnos Sciences SA)
  • P-BCMA-101 CAR-T cells: Poseida Therapeutics
  • Opdivo (Nivolumab): Bristol-Myers Squibb
  • PBCAR269A: Precision BioSciences
  • MP0250: Molecular Partners AG
  • Teclistamab (JNJ-7957; JNJ-64007957): Janssen Pharmaceutical
  • Descartes-11: Cartesian Therapeutics
  • Imfinzi (Durvalumab): AstraZeneca
  • Imbruvica (Ibrutinib): Abbvie (Pharmacyclics) and Johnson & Johnson

 

Download the report to understand which factors are driving Multiple Myeloma Market Trends @ Multiple Myeloma Market Outlook

 

Scope of the Multiple Myeloma Market Research Report

  • Coverage- 7MM
  • Study Period- 2019-2032
  • Forecast Period- 2022-2032
  • Multiple MyelomaCompanies- GlaxoSmithKline, Bristol-Myers Squibb/Bluebird bio, Oncopeptides AB, Secura Bio, Amgen (Onyx therapeutics), Takeda Pharmaceutical (Millennium Pharmaceuticals), Sanofi, Karyopharm Therapeutics, Janssen Biotech, Bristol Myers Squibb/AbbVie, Takeda Pharmaceutical/Janssen Pharmaceutical, Bristol-Myers Squibb Company (Celgene), Celgene (BMS), Bristol-Myers Squibb/Celgene, RAPA Therapeutics, Pfizer (Array Biopharma),  Cellectar Biosciences, BioLineRx, Celgene/Aduro Biotech, ExCellThera, Janssen Pharmaceutical, Precision BioSciences, Takeda, Glenmark (Ichnos Sciences SA), Poseida Therapeutics, Molecular Partners AG, Chipscreen Biosciences, AbbVie/Genentech (Roche), Janssen Biotech/Nanjing Legend Biotech, Merck Sharp & Dohme Corp., Janssen, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Cartesian Therapeutics, AstraZeneca, Abbvie (Pharmacyclics) and Johnson & Johnson, MorphoSys AG/I-Mab Biopharmam, and others.
  • Multiple Myeloma Pipeline Therapies- belantamab mafodotin, Pembrolizumab, Melphalan flufenamide (Melflufen), Dexamethasone, Elotuzumab, Bortezomib, BT062, bb2121, Venetoclax, Bortezomib, Melphalan, Panobinostat, VELCADE (bortezomib), cyclophosphamide, and others.

 

Table of Content

1. Key Insights

2. Multiple Myeloma Report Introduction

3. Multiple Myeloma Market Overview at a Glance

4. Multiple Myeloma Executive Summary

5. Multiple Myeloma Epidemiology and Market Forecast Flow

6. Disease Background and Overview

8. Multiple Myeloma Treatment

9. Multiple Myeloma Epidemiology and Patient Population

10. Patient Journey

11. Key Endpoints in Multiple Myeloma

12. Multiple Myeloma Marketed Therapies

13. Multiple Myeloma Emerging Therapies

14. Multiple Myeloma: Eight Major Market Analysis

15.  Market Access and Reimbursement of Multiple Myeloma Therapies

16. Multiple Myeloma Market Drivers

17. Multiple Myeloma Market Barriers

18. Multiple Myeloma SWOT Analysis

19. Multiple Myeloma Unmet Needs

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

 

Got Queries? Consult with our Business Expert @ Multiple Myeloma Market Drivers and Barriers

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/